Evidence map›Paper›PMID 28090225›Full record

ArticleJournal of clinical medicine research2017

Efficacy and Safety of Combination Therapy Consisting of Angiotensin II Type 1 Receptor Blocker, Calcium Channel Blocker and Hydrochlorothiazide in Patients With Hypertension.

Yuhei Shiga, Shin-Ichiro Miura, Kota Motozato, Yuka Yoshimine, Kenji Norimatsu, Tadaaki Arimura, Rie Koyoshi, Joji Morii, Takashi Kuwano, Ken Inoue and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Yuhei ShigaDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan; Inoue Hospital, Fukuoka, Japan; Shirotani Hospital, Fukuoka, Japan.
Shin-Ichiro MiuraDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
Kota MotozatoDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan; Fujisawa Clinic, Fukuoka, Japan.
Yuka YoshimineDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan; Inoue Hospital, Fukuoka, Japan.
Kenji NorimatsuDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
Tadaaki ArimuraDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
Rie KoyoshiDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan; Matsunaga Hospital, Fukuoka, Japan.
Joji MoriiDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
Takashi KuwanoDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
Ken InoueInoue Hospital, Fukuoka, Japan.
Tetsuro ShirotaniShirotani Hospital, Fukuoka, Japan.
Kazuaki FujisawaFujisawa Clinic, Fukuoka, Japan.
Eiyu MatsunagaMatsunaga Hospital, Fukuoka, Japan.
Keijiro SakuDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
Fukuoka University · JPFujisawa City Hospital · JPInoue Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany patients continue to have high blood pressure (BP) even after treatment with high-dose (H)-angiotensin II type 1 receptor blocker (ARB)/calcium channel blocker (CCB) or middle-dose (M)-ARB/CCB/hydrochlorothiazide (HCTZ).

methodsThirty-two hypertensive patients who had the use of H-ARB/CCB or M-ARB/CCB/HCTZ were enrolled in this study. We applied a changeover with a switch to H-ARB (telmisartan 80 mg/day)/CCB (amlodipine 5 mg/day or nifedipine CR 40 mg/day)/HCTZ (12.5 mg/day).

resultsSystolic BP (SBP) and diastolic BP (DBP) were significantly decreased in all patients and in the H-ARB/CCB and M-ARB/CCB/HCTZ groups after 3 months. Percentage (%) of patients who reached the target BP after 3 months (72%) in all patients was significantly higher than that at 0 months (19%). There were no serious adverse effects in any of the patients.

conclusionsCombination therapy with H-ARB/CCB/HCTZ was associated with a significant reduction of BP.

Indexed as

Angiotensin II type 1 receptor blockerBlood pressureCalcium channel blockerHydrochlorothiazide

Identifiers

PMID28090225
PMCPMC5215013
OpenAlexW2566494903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.